Back to search
FDAFDA · Food and drugs·Recall number D-0884-2022

Trulicity (dulaglutide) injection, 0.75 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 0002-1433-80

Published May 25, 2022 · Recall initiated: April 5, 2022

Summary

FDA records drug Class II recall D-0884-2022, published May 25, 2022 and initiated April 5, 2022. Recalling firm: Cardinal Health Inc.; Status: Completed; Reported quantity: 1 box; Lot: Lot #: D484557A, Exp: 10/25/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions

What to do

Voluntary: Firm initiated · Letter

Get an email if TRULICITY has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TRULICITY
Manufacturer
Cardinal Health Inc.
Distributor
NM only
Lot
Lot #: D484557A, Exp: 10/25/2023.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Trulicity (dulaglutide) injection, 0.75 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 0002-1433-80 recalled?

Yes. FDA published recall D-0884-2022 on May 25, 2022. Reported hazard: TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TRULICITY.